| 1. |
A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage. （ポスター，一般） 2023/12
|
| 2. |
Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes. （口頭発表，一般） 2023/12
|
| 3. |
Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma. （ポスター，一般） 2023/12
|
| 4. |
The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma. （ポスター，一般） 2023/12
|
| 5. |
JAK2V617F遺伝子変異陽性の本体性血小板血症から移行したt(8;21)陽性急性骨髄性白血病 （口頭発表，一般） 2023/10
|
| 6. |
Von Willebrand病type再判断のための医療連携の必要性とその手順 （口頭発表，一般） 2023/10
|
| 7. |
低形成骨髄を呈した本態性血小板血症 （口頭発表，一般） 2023/10
|
| 8. |
３系統の免疫性血球減少を呈した骨髄病変を有するIgG4関連疾患 （口頭発表，一般） 2023/10
|
| 9. |
A phase 3 trial of bendamustine/rituximab for relapsed or refractory diffuse large b-cell lymphoma （口頭発表，一般） 2021/09
|
| 10. |
Blastic plasmacytoid dendritic cell neoplasm lacking CD4 expression （ポスター，一般） 2021/09
|
| 11. |
Co-expression of chromosomal abnormalities predict poor responsibility for EPD treatment （ポスター，一般） 2021/09
|
| 12. |
Long term prognosis of patient with chronic DIC who has ITP （ポスター，一般） 2021/09
|
| 13. |
Two cases of lymphoplasmacytic lymphoma presenting lymphomatous infiltration of the kidneys （ポスター，一般） 2021/09
|
| 14. |
免疫性血小板減少症の経過中に顕在化しTKI 治療により血小板の増加が得られた慢性骨髄性白血病 （口頭発表，一般） 2021/03
|
| 15. |
Carfilzomib regimen in patients with multiple myeloma intolerable or relapsed to VRD induction （口頭発表，一般） 2020/10
|
| 16. |
Efficacy and safety of bendamustine in elderly patients with R/R low-grade B-cell lymphoma and MCL （口頭発表，一般） 2020/10
|
| 17. |
Final analysis of a phase 2 study of ixazomib plus LenDex in Japanese RRMM patients （口頭発表，一般） 2020/10
|
| 18. |
KEYNOTE-204: phase 3 study of pembrolizumab vs brentuximab vedotin in R/R classical Hodgkin lymphoma （口頭発表，一般） 2020/10
|
| 19. |
Phase 2 study of E7777 on relapsed or refractory, peripheral and cutaneous T-cell lymphoma in Japan （口頭発表，一般） 2020/10
|
| 20. |
Phase II study of tirabrutinib in Japanese patients with Waldenstrom's macroglobulinemia （口頭発表，一般） 2020/10
|
| 21. |
Polatuzumab vedotin with bendamustine and rituximab in r/r DLBCL (P-DRIVE): A phase 2 study in Japan （口頭発表，一般） 2020/10
|
| 22. |
Transformed follicular lymphoma in relation with rituximab maintenance and chromosome 8 aberrations （口頭発表，一般） 2020/10
|
|
5件表示
|
|
全件表示(22件)
|